# Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)

> **NCT04097275** · — · UNKNOWN · sponsor: **CENTOGENE GmbH Rostock** · enrollment: 1000 (estimated)

## Conditions studied

- Inborn Errors of Metabolism

## Interventions

- **OTHER:** Skin biopsy
- **OTHER:** Withdraw of blood

## Key facts

- **NCT ID:** NCT04097275
- **Lead sponsor:** CENTOGENE GmbH Rostock
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097275, "Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04097275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*